A Milestone Moment: FDA Approves Addyi® for Hypoactive Sexual Desire Disorder in Postmenopausal Women
December 17, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
No Data Available.
Synonyms :
Class :
Acetylcholinesterase Inhibitors and irreversible anticholinesterases
Brand Name :
No Data Available.
Synonyms :
Class :
Acetylcholinesterase Inhibitors and irreversible anticholinesterases
Dosage Forms & Strengths Â
ophthalmic solution Â
0.125% Â
Dosage Forms & Strengths Â
ophthalmic solution Â
0.125% Â
It May reduce the therapeutic effect of Echothiophate Iodide 
It may increase the level of serum concentration of Mivacurium
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic (central) effect
may increase the neurotoxic (central) effect
may increase the neurotoxic (central) effect
may increase the neurotoxic (central) effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
May diminish the therapeutic effect of Anticholinergic Agents
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may decrease the therapeutic effect of Anticholinergic Agents
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the risk of adverse effect
may enhance the risk of adverse effect
may enhance the risk of adverse effect
may enhance the risk of adverse effect
may enhance the risk of adverse effect
may decrease the therapeutic effect of Acetylcholinesterase Inhibitors
It may enhance the risk of adverse effects when combined with coronary vasodilators
It may enhance the risk of adverse effects when combined with coronary vasodilators
Adverse drug reactions: Â
Frequency Not Defined Â
Bradycardia Â
Flushing Â
Hypotension Â
Stinging Â
Lacrimation Â
Iris cyst formation Â
Burning Â
Diarrhea Â
Myopia Â
Uveitis activation Â
Lens opacities Â
Nausea Â
Vomiting Â
Blurred vision Â
Ciliary redness Â
Increased intraocular pressure Â
Miosis Â
Â
Pregnancy warnings:   Â
Pregnancy Category: CÂ
Breastfeeding warnings:Â
The release of the drug into the human breastmilk is unknown Â
Pregnancy Categories:     Â
Â
Patient Information Leaflet Â
Generic Name: echothiophateÂ
Pronounciation: eck-oh-THIGH-oh-fateÂ
Why do we use echothiophate?Â
echothiophate belongs to the class of irreversible anticholinesterases used to treat Accommodative Esotropia, Open Angle or Secondary Glaucoma, and Advanced Chronic Simple Glaucoma/Glaucoma Following Cataract SurgeryÂ
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
